Evidence map›Paper›PMID 40895556›Full record

ReviewFrontiers in immunology2025

Ferroptosis-immune crosstalk in cervical cancer: mechanisms and therapeutic implications.

Lili Li, Yunfeng Bo, Dan Xue, Lijuan Qin

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lili Li *Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, ShanXi, China.
Yunfeng Bo *Department of Pathology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China.
Dan XueShanxi Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No.3 Zhigong Xincun Street, Xinghualing District, Taiyuan, Shanxi, China.
Lijuan QinDepartment of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, ShanXi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer remains a leading cause of cancer-related mortality in women worldwide, particularly in regions with limited access to screening and vaccination. While immunotherapy has shown promise in treating advanced cervical cancer, immune evasion mechanisms within the tumor microenvironment continue to limit therapeutic efficacy. Ferroptosis, a form of iron-dependent regulated cell death characterized by lipid peroxidation, has recently been recognized as a crucial regulator of tumor progression and immune modulation. Emerging evidence suggests that ferroptosis interacts with immune signaling pathways, contributing to immune suppression, antigen presentation defects, and the remodeling of the tumor immune microenvironment in cervical cancer. This review highlights the current understanding of ferroptosis-related mechanisms underlying immune evasion in cervical cancer, including alterations in ferroptosis regulators, redox imbalance, and ferroptosis-induced release of immunomodulatory molecules. We further explore how targeting ferroptosis may enhance anti-tumor immunity and overcome resistance to immunotherapy. Finally, we discuss recent advances in ferroptosis-based therapeutic strategies and identify future directions for integrating ferroptosis modulation into cervical cancer treatment.

Indexed as

FerroptosisUterine Cervical NeoplasmsAnimalsFemaleHumansImmunotherapySignal TransductionTumor EscapeTumor Microenvironmentcervical cancerferroptosisimmune evasionimmunotherapytumor microenvironment

Identifiers

PMID40895556
PMCPMC12395990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.